CELUCelularity Inc. Class A Common Stock
0.8000USD+2.83%Mkt Cap: 23.16M $P/E: —3d ago
Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBa…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
| Headline | Source | Time |
|---|---|---|
Older | ||
NexGel Files to Register 15.25 Million Shares From Note Conversions NexGel (NXGL) on Thursday filed a prospectus to register the resale of 15.25 million shares of commo | MMT Newswires | |
 NEXGEL Q2 Revenue Reaches $3.69 Million as BioNX Integration Faces Slower Ramp NEXGEL (NASDAQ:NXGL) reported second-quarter 2026 revenue of $3. 69 million and a net loss of $2. | ||